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Abstract
Background: Microparticles (MPs) are small vesicles released during cell activation or apoptosis. They are involved in
coagulation, inflammation and vascular dysfunction in several diseases. We characterized circulating MPs from Crohn’s
Disease (CD) patients and evaluated their effects on endothelial function and vascular reactivity after in vivo injection into
mice.
Methods: Circulating MPs and their cellular origins were examined by flow cytometry from blood samples from healthy
subjects (HS) and inactive or active CD patients. MPs were intravenously injected into mice. After 24 hours, endothelial
function and vascular reactivity were assessed.
Results: Circulating MP levels did not differ between HS and inactive CD patients except for an increase in leukocyte-derived
MPs in CD. Active CD patients compared to HS displayed increased total circulating MPs, pro-coagulant MPs and those from
platelets, endothelium, erythrocytes, leukocytes, activated leukocytes and activated platelets. A significant correlation was
found between total levels of MPs, those from platelets and endothelial cells, and the Harvey-Bradshaw clinical activity
index. MPs from CD, but not from HS, impaired endothelium-dependent relaxation in mice aorta and flow-induced dilation
in mice small mesenteric arteries, MPs from inactive CD patients being more effective than those from active patients.
CDMPs induced vascular hypo-reactivity in aorta that was prevented by a nitric oxide (NO)-synthase inhibitor, and was
associated with a subtle alteration of the balance between NO, reactive oxygen species and the release of COX metabolites.
Conclusions: We provide evidence that MPs from CD patients significantly alter endothelial and vascular function and
therefore, may play a role in CD pathophysiology, at least by contributing to uncontrolled vascular-dependent intestinal
damage.
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Introduction
Crohn’s disease (CD) is a relapsing digestive inflammatory
disorder whose causes remain still unknown. It is usually accepted
that three main interacting actors contribute to its pathophysiol-
ogy: a genetic susceptibility, environmental factors (especially
smoking), and priming by the enteric flora (also called microbiota)
[1–5]. As a result, inappropriate intestinal inflammatory and
immune responses occur and lead to immune-mediated tissue
injury and the subsequent clinical symptoms and signs of the
disease. Beside this current pathophysiological hypothesis, several
data indicate that CD is also associated with intestinal microvas-
cular dysfunction [6,7]. Early studies showed occlusion of the
vessels supplying the mesenteric margin that might cause ischemia
in CD inflamed terminal ileum [8]. Moreover, it has been
observed that mesenteric vascular damage appears before
inflammatory infiltration of the intestinal lamina propria [9].
Peripheral arterial mesenteric thrombosis and multifocal mesen-
teric ischemic infarction in distal small arteries at the mesenteric
border, next to the mucosal lesions have also been reported in CD
[10].
Among the direct consequences of these vascular alterations, the
risk of peripheral mesenteric microthrombosis, endothelial dys-
function and modifications of vascular tone are well described
[11,12]. In submucosal arterioles isolated from areas of chronic
intestinal inflammatory damage from inflammatory bowel disease
(IBD) [CD and ulcerative colitis (UC)] patients, endothelial
dysfunction has been shown to be associated with reduced nitric
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oxide (NO) and increased oxidative stress [13]. However, other
authors described an unchanged endothelium-dependent and -
independent relaxation in the mesenteric arteries from CD
patients but a decrease of vascular tone [14]. In contrast to these
results, we found no modification on vascular reactivity of small
mesenteric arteries (SMA) from CD patients despite an increased
release of proinflammatory cytokines from their intestinal mucosa.
Indeed, we found that a balance between vasoconstrictor products
from cyclo-oxygenase-2 (COX-2) and unidentified vasodilator
products may explain that vascular reactivity remained unchanged
[15].
Functional alterations in inflamed gut can result from over-
production of different inflammatory mediators including not only
NO and eicosanoids but also endotoxins and cytokines [16]. Other
factors that may trigger these effects can be circulating micropar-
ticles (MPs) which are small membrane vesicles shed from cells in
response to activation or apoptosis [17–21]. Present in blood of
healthy subjects (HS), MPs have been studied in various diseases,
like diabetes, metabolic syndrome, sepsis or obstructive sleep
apnoea in which their number, cellular source or composition are
altered [22–25]. MPs might play a major role in interactions with
circulating cells or the components of the vessel wall. Indeed, they
have been implicated in coagulation, inflammation and vascular
function [19,20,26–28].
In active CD patients, increased circulating levels of pro-
coagulant MPs that are reduced upon treatment with infliximab
with no correlation to the clinical Van Hees activity index have
been reported [29]. On the other hand, elevated MP levels derived
from platelets correlated with CD Activity Index (CDAI) and
activation of platelet aggregation evaluated by P-selectin expres-
sion. The level of platelet MPs decreased after remission of the
disease [30].
To the best of our knowledge, studies analysing total circulating
MPs and their cellular origins with clinical characteristics of CD
patients has never been assessed in details. Moreover, the role of
these MPs in the regulation of endothelial dysfunction and
vascular reactivity in CD patients is not known. Thus, the aim of
this work was to characterize circulating MPs from patients with
CD according to their cellular origins and their correlation with
clinical status. Then, MPs were injected intravenously into mice to
test their effects on both endothelial function and vascular
reactivity in conductance arteries and SMA.
Materials and Methods
Patients
Thirty nine adult patients (27 women, 12 men) with CD
according to the Lennard-Jones criteria [31] were recruited at the
Service d’He´pato-Gastro-Ente´rologie et Nutrition from the Caen
University Hospital (CHU de Caen, France). Patients were
considered for enrolment if they are referred to the Medical
Centre for the treatment of active luminal CD, for maintenance
treatment in inactive CD or for surveillance clinical visit if they
were older than 18 years and if they had no exclusion criteria.
Exclusion criteria were: current or recent (at least 1 month before)
intestinal infection or infectious complication of CD, extra-
digestive infection, or pregnancy. Clinical activity was determined
using the Harvey-Bradshaw index [32]. This index allows an
instantaneous calculation of disease activity using clinical items at
the time of hospitalization or surveillance outpatients visit, by
contrast to the CD Activity Index (CDAI) which needs the record
of clinical symptoms during the 7 days before calculation of disease
activity. A good correlation has been reported between the
Harvey-Bradshaw index and the CDAI [32]. The clinical items
recorded to determine the Harvey-Bradshaw index are: (i) number
of liquid or soft stools per day, (ii) abdominal pain (none = 0,
mild = 1, moderate = 2, severe = 3), (iii) general well-being (very
well = 0, slightly below par = 1, poor = 2, very poor = 3, terri-
ble = 5), (iv) presence of abdominal mass at clinical examination
(non = 0, dubious = 1, definite = 2, definite and tender = 3), and (v)
presence of the following complications (arthralgia, uveitis,
erythema nodosum, aphtous ulcers in mouth, anal fissure, anal
fistula, abscess; 1 point for each if present). Disease was considered
inactive if the Harvey-Bradshaw index was ,4, active if the
Harvey-Bradshaw index was comprised between 4 and 12, active
and severe when the Harvey-Bradshaw index was .12. Their
median age was 31 years (extremes: 19–60). Clinical characteristics
of patients were summarized in Table 1.
Biological parameters (as well as the Harvey-Bradshaw index)
were also determined at the time of blood collection for MP
isolation in CD patients (usually the day following their admission
at hospital). These include total leukocytes, polymorphonuclear
leukocytes (PMN), lymphocytes and platelet counts, haemoglobin
level, C-reactive protein (CRP) (mg/L) and albumin (g/L)
concentrations.
The control group consisted of 28 healthy subjects (named HS
or controls: 13 women, 15 men) aged 25.5 years old (22–56;
p = 0.15 compared to the CD patients group). HS had no history
of digestive or extra-digestive disease, had no familial history of
digestive disorders (in particular history of IBD), and, except oral
contraception in women, do not take any medication.
In accordance with the ethical guidelines of the Declaration of
Helsinki and the ethical French guidelines, the local Ethics
Committee [Comite´ de Protection des Personnes (CPP) Nord-
Ouest III, Caen, France] approved the study. The Agence
Franc¸aise de Se´curite´ Sanitaire des Produits de Sante´ (AFSSAPS),
a French regulatory health authority approved also the study. All
subjects provided written informed consent.
Blood Collection and Cell-derived Circulating MP
Isolation
Blood samples from CD patients and HS (20 mL) were
collected by sterile venous puncture in trisodium citrate glass
tubes (Vacutainer, Becton Dickinson, Le Pont de Claix, France) at
a final volume ratio of 9:1. Blood collection was performed in the
morning in overnight fasting patients and controls. The MP
isolation procedure began less than 30 minutes after blood
collection. Samples were centrifuged as previously described
[23–25]. Briefly, samples were centrifuged for 20 minutes at
270 g, and plasma was then harvested and centrifuged at 1,500 g
in order to obtain platelet-free plasma (PFP). Two hundred mL of
PFP were immediately frozen and stored at 280uC until
subsequent use. Then, remaining PFP was subjected to three
series of centrifugations at 21,000 g for 90 minutes in order to
eliminate plasma and to pellet MPs for the subsequent in vivo
studies. Supernatant was replaced by 0.9% saline salt solution [23–
25]. Finally, MP pellets were resuspended in 200 mL of 0.9%
saline salt solution and stored at 4uC until subsequent use. Saline
salt solution for the last supernatant was used as control (vehicle).
Characterisation of MP Phenotype
MP subpopulations were characterised in PFP according to the
expression of membrane-specific antigens by flow cytometry [23–
25]. MPs derived from platelets, erythrocytes, leukocytes, endo-
thelial cells and granulocytes were identified using anti-CD41,
anti-CD235a, anti-CD45, anti-CD146 and anti-CD66b antibod-
ies, respectively. Anti-CD62P and anti-CD62L antibodies were
used to identify P-selectin-positive and L-selectin-positive MPs,
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respectively. Irrelevant human IgG was used as an isotype-
matched negative control for each sample. Annexin-V (Beckman
Coulter, Villepinte, France) binding was used to numerate
phosphatidylserine-expressing MPs (2 mL of annexin-V/5 mL
PFP). To determine MPs concentrations, 10 mL of PFP were
incubated with 5 mL of specific antibody (Beckman Coulter). After
45 minutes of incubation, samples were diluted in 300 mL of 0.9%
saline salt solution or annexin-V labelling buffer, respectively.
Then, an equal volume of sample and Flow-count fluorospheres
(Beckman Coulter) were added in order to calculate MP
concentration The Flow-count fluorospheres were used to quantify
MPs. Each lot of Flow-count fluorospheres has a specific
concentration of fluorospheres. When identical volumes of a
sample and Flow-count fluorospheres are used, a ratio of MPs in
the sample to fluorospheres is established. Since the concentration
of fluorospheres is known, the absolute count of the MPs can be
determined using the MXP software (Beckman Coulter). The
samples were analysed in a flow cytometer 500 MPL System
(Beckman Coulter). Sample analysis was stopped after the count of
10,000 events.
Vascular Reactivity
All animal studies were performed using approved institutional
protocols. The protocol was approved by The Committee on the
Ethics of Animal Experiments of CEEA Pays de la Loire (Permit
Number: CEEA.2009.9). MPs were injected into the tail vein in
male Swiss mice (6–8 week old) at the circulating level of MPs
detected in the blood of CD patients (CDMPs) and HS (HSMPs)
or with saline salt solution (vehicle). These values ranged from
1,642 to 63,184 MPs/mL of plasma for healthy subjects and 1,396
to 18,944 MPs/mL of plasma for CD patients, indicating that
several healthy subjects had circulating levels of MPs greater than
several CD patients. Using MPs from other pathologies, we have
previously shown that the duration of 24 hours treatment with
MPs induced changes of vascular function. Furthermore, the
injection of MPs from human subjects in mice for 24 hours did not
induce immunological reactions under the same experimental
conditions [23–25]. Non-invasive blood pressure was measured by
tail-cuff method (Letica, Barcelona, Spain) in animals before and
24 hours after MP injection. Animals were trained everyday over a
period of a week to get accustomed to the device. A total of 10
consecutive readings of systolic pressure and heart rate were daily
recorded and averaged. Twenty-four hours after having been
injected, mice were sacrificed and aortic rings and SMA were
isolated and segments (2 mm-long) were mounted on a wire
myograph and arteriograph for measurement of vascular reactiv-
ity. The functionality of the endothelium was assessed by
cumulative application of acetylcholine (1 nmol/L-10 mmol/L,
Sigma-Aldrich, St. Quentin, Fallavier, France) in aortas precon-
tracted with U46619 (0.1 mmol/L, Sigma-Aldrich).
SMA (100 to 130 mm in diameter) were mounted in a video-
monitored perfusion system (Living Systems Instrumentation,
Burlington, VT) to study the physiological endothelial dilatation
in response to shear stress. Diameter changes were measured by
increasing flow rate (0 to 92 mL/min) under a constant intralu-
minal pressure of 75 mm Hg. The integrity of the endothelium
was studied by using acetylcholine (10 mmol/L) in the arteries pre-
contracted with U46619 (1 mmol/L). The different components of
the dilation were determined by using the following inhibitors: the
NO-synthase inhibitor NG-nitro-L-arginine (L-NA, 100 mmol/L;
Sigma Aldrich), the non-selective COX inhibitor indomethacin
(10 mmol/L; Sigma Aldrich). The NO, COX and the endothelial-
derived hyperpolarizing factor (EDHF) component of the response
of dilation were calculated as previously described [25]. Vascular
reactivity was evaluated by cumulative application of serotonin (5-
HT, 3 nmol/L-10 mmol/L; Sigma Aldrich) to vessels with
functional endothelium in the absence or presence of the given
inhibitor: L-NA (100 mmol/L), indomethacin (10 mmol/L), the
selective COX-1 inhibitor 5-(4-Chlorophenyl)-1-(4-methoxyphe-
nyl)-3-trifluoromethyl pyrazole (SC-560 10, mmol/L) and the
selective COX-2 inhibitor N-(2-cyclohexyloxy-4-nitrophenyl)
methanesulfonamide (NS-398, 10 mmol/L; Sigma Aldrich). All
inhibitors were used at maximal active concentrations as reported
in many of our previous studies [24,25,27].
NO Spin Trapping and Electronic Paramagnetic
Resonance (EPR) Studies
The detection of NO production was performed using the
technique with Fe2+ diethyldithiocarbamate (DETC, Sigma
Aldrich) as spin trap. Isolated aortas from mice injected
respectively with CDMPs, HSMPs and vehicle were incubated
for 45 minutes in Krebs-Hepes buffer (BSA (20.5 g/L), CaCl2
Table 1. Clinical characteristics of Crohn’s disease (CD) patients.
Inactive CD patients (n= 13) Active CD patients (n= 26)
Gender (women/men) 7/6 20/6
Age (median, extremes) 37 (19–59) 28 (19/60)
Disease activity: Harvey-Bradshaw index (HB)
median (extremes)
HB: 1 (0–3) HB: 10 (5–21); Non-severe: n= 15; HB: 9 (5–10); Severe:
n= 11; HB: 14 (13–21)
Disease duration (months) (median, extremes) 108 (17–304) 84 (0.5–276)
Type of Crohn’s disease Inflammatory: n= 9; Stenotic: n= 4 Inflammatory: n= 22; Stenotic: n= 4
Extension Only ileal: n= 4; Only colonic: n= 4; Ileocolonic: n= 5 Only ileal: n= 5; Only colonic: n= 10; Ileocolonic: n = 11
Perineal disease (yes/no) 4/9 7/19
Treatment* No treatment: n= 0; Corticosteroids: n= 7; Azathioprine:
n= 3; Methotrexate: n= 1; Anti-TNF mAb**: n = 9
No treatment: n= 11; Corticosteroids: n= 8;
Azathioprine: n= 7; Methotrexate: n= 2; Anti-TNF
mAb**: n= 5
Previous surgery (ileocolonic resection)*** (yes/no) 2/11 2/24
*Total is higher than the number of patients as some of them receive combination of medication.
**mAb: Monoclonal antibody. All patients, except two in the active CD patients group failing adalimumab therapy at the time of inclusion, received infliximab.
***Except ileocolonic resection no patient had underwent other type of small bowel and/or colonic surgery.
doi:10.1371/journal.pone.0073088.t001
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(3 mmol/L) and L-arginine (0.8 mmol/L)) and after treated with
250 mL of colloid Fe(DETC)2 and incubated at 37uC for 45
minutes [24,33]. The organs were immediately frozen in plastic
tubes. NO measurements were performed on a tabletop x-band
spectrometer miniscope (MS200; Magnettech, Berlin, Germany).
Values are expressed as amplitude of signal per weight of dried
tissue.
Superoxide Anion (O2
2) Determination by EPR
The aortas isolated from mice injected with CDMPs, HSMPs or
vehicle were dissected and allowed to equilibrate in deferoxamine-
chelated Krebs-Hepes solution containing 1-hydroxy-3-methox-
ycarbonyl-2,2,5,5-tetramethylpyrrolidin (CMH; Noxygen, Mainz,
Germany) (500 mmol/L), deferoxamine (25 mmol/L), and DETC
(5 mmol/L) under constant temperature (37uC) for 45 minutes.
The reaction was stopped by putting samples on ice. The organs
were frozen in plastic tubes and analyzed in a Dewar flask by EPR
spectroscopy [24]. Values are expressed as amplitude of signal per
weight of dried tissue.
Western Blotting
The aortas isolated from mice injected respectively with vehicle,
HSMPs and active CDMPs were dissected and homogenized for
protein extraction. Proteins (40 mg) were separated using 10%
sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Blots
were probed with anti-inducible NOS (iNOS) (BD Bioscences, San
Jose, CA). A polyclonal rabbit anti-mouse b-actin antibody (Sigma
Aldrich) was used as a loading control. Membranes were washed
at least three times in Tris-buffer solution containing 0.05%
Tween and incubated for 1 h at room temperature with the
horseradish peroxidase (HRP)-conjugated secondary antibody
(Amersham, Piscataway, NJ). Protein bands were detected by
SuperSignal West Femto Maximum Sensitivity Substrate (Pierce,
Rockford, IL) according to the protocol of the manufacturer.
Data Analysis
Data are represented as mean 6 SEM, n represents the number
of patients or mice. In mouse aorta studies, each condition was
performed by duplicate (2 rings from the same mouse). Statistical
analyses were performed by a one-way analysis of variance and
Mann- Whitney U-test for data analysis between groups or two-
way analysis of variance for repeated measures and subsequent
Bonferroni post hoc test. P,0.05 was considered to be statistically
significant.
Results
Patient Characteristics
Clinical characteristic of CD patients are summarized on
Table 1. Twenty six patients had active CD with a median
Harvey-Bradshaw index of 10 (5–21), among which 15 were
considered as having active non-severe disease and 11 patients
presenting severe disease. Thirteen CD patients had inactive
disease (median Harvey-Bradshaw index: 1 (0–3)).
Neither age nor disease extension were statistically different
between inactive and active CD patients. CD patients received
infliximab (n= 12), adalimumab (n= 2), azathioprine (n= 10),
methotrexate (n= 3) or oral prednisone (n= 12), or oral budesonide
(n= 3).
CRP concentration was significantly higher in active CD
patients, whereas albumin concentration was significantly lower
compared to inactive CD patients. Total leukocytes, PMN, and
lymphocytes were not different between active and inactive CD
patients. Platelet count was significantly increased in active CD
patients whereas haemoglobin was decreased (Table 2). Finally,
Harvey-Bradshaw index was positively correlated to CRP
concentration (r’ = 0.70, p,0.0001) and negatively to albumin
concentration (r’ =20.52, p = 0.042). CRP and albumin concen-
trations were negatively correlated to each other (r’ =20.67,
p = 0.0002).
Circulating MPs and their Cellular Origin
The total number of circulating MPs was significantly increased
in active CD patients compared with HS and inactive CD patients
(Figure 1C). Phenotypical characterisation of cellular origin of
MPs from HS and inactive CD patients did not show significant
difference between the two groups except that of leukocytes
(CD45+) MPs (Figure 1D–1H). Interestingly, compared to HS,
active CD patients displayed increases of pro-coagulant (annexing
V+) MPs and those from platelets (CD41+), endothelial cells
(CD146+), leukocytes (CD45+), erythrocytes (CD235a+), activated
leukocytes (CD62L+) and activated platelets (CD62P+) (Figure 1D–
1H). MPs from macrophages (CD11b+) and granulocytes
(CD66b+) were not significantly different between HS and active
CD patients (not shown). Finally, active CD patients showed
increased total circulating MPs, platelet- and endothelial-derived
MPs when compared to inactive patients (Figure 1C, 1D and 1F).
Relation between MP Levels and Clinical Characteristics
Total MP concentration was not correlated to disease duration
(r’ = 0.104, p = 0.55). Correlation analysis for disease activity
Table 2. Biological parameters of inactive and active Crohn’s disease (CD) patients.
Inactive CD patients (n =13) Active CD patients (n= 26)
C-reactive protein (CRP) (mg/L) 2.9060.75 47.22611.58***
Albumin (g/L) 39.0761.26 32.2861.55**
Total leukocytes (number/mm3) 8,1406971 8,2566725
Polymorphonuclear leukocytes (number/mm3) 5,4586956 4,8596531
Lymphocytes (number/mm3) 2,1256337 2,2536208
Platelets (number/mm3) 271,385621,614 435,286633,651*
Hemoglobin (g/dL) 13.360.3 11.660.5*
*p,0.05,
**p,0.01,
***p,0.001 vs inactive CD patients.
doi:10.1371/journal.pone.0073088.t002
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showed that total circulating MPs and those from platelets and
endothelial cells were positively correlated to the Harvey-
Bradshaw index (Figure 2A–2C).
Among biological data, total circulating MPs, pro-coagulant,
platelet-, endothelial- and erythrocyte MPs were correlated to
CRP. Only a trend of correlation was observed for activated
leukocyte MPs. There was no correlation between total MPs with
albumin concentration, haemoglobin level, leukocytes, PMN or
lymphocyte counts, although there was a trend with platelet count.
Endothelial-derived MPs were negatively correlated to albumin
concentration (Table 3). There was no correlation between the
levels of macrophage-, leukocyte-, granulocyte- and activated
platelet-MPs with other measured biological characteristics of CD
patients (data not shown).
Neither total MPs nor their cellular origins were significantly
different considering disease extension despite a trend to a
decrease in ileal compared to colonic or ileocolonic CD for
CD62P+ MP levels (p = 0.0723).
Figure 1. Circulatingmicroparticles (MPs) from healthy subjects (HS) (A) and Crohn’s disease (CD) patients (B) and Flowcount beads
(Beads region, 10 mm diameter) are visualized in a side scatter (SS)/forward scatter (FS) logarithmic representation. MPs are defined
as events with size 0.1 to 1 mm gated in the ‘‘MPs’’ window. Circulating MP levels in patients with inactive CD and active CD compared to HS. Total
circulating MPs (C), CD41+ MPs (D), annexin V+ MPs (E), CD146+ MPs (F), CD45+ and CD235a+ MPs (G), CD62L+ and CD62P+ MPs (H). MPs from HS
(n=28), MPs from inactive CD patients (inactive CD n=13) and MPs from active CD patients (active CD n=26). Results are expressed as events/mL of
plasma and given as mean 6 SEM. *p,0.05, ***p,0.001 vs HS; {p,0.05, {{p,0.01 active CD vs inactive CD.
doi:10.1371/journal.pone.0073088.g001
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The type of disease (‘‘stenotic’’, ‘‘inflammatory’’) did not
influence MP levels. Patients with perineal disease showed lower
levels of CD66b+ MPs (p = 0.0207) and a trend to lower CD235a+
MPs (p = 0.074).
MPs from CD Induce Endothelial Dysfunction in Aorta
and SMA
The endothelium-dependent relaxation to acetylcholine was
significantly impaired in aorta isolated from mice injected with
CDMPs compared to aorta isolated from mice injected either with
vehicle or with HSMPs (Emax: 69.362.1%, 65.262% and
45.161.02% for CTL, HSMPS and CDMPs, respectively
p,0.001) (Figure 3A). Injection of either inactive or active
CDMPs reduced acetylcholine-induced aortic endothelium-de-
pendent relaxation when compared to those taken from HSMP-
treated mice. Unexpectedly, inactive CDMPs were more effective
than active CDMPs in impairing endothelial function (Emax
inactive CDMPs 41.261.3%; Emax active CDMPs 49.861.03%;
p,0.01) (Figure 3B).
In SMA, HSMPs significantly enhanced flow-induced dilation
when compared to control (Figure 4A), due to increased EDHF-
component of the response (Figure 4B). Compared to control,
inactive CDMPs (p,0.001) but not active CDMPs reduced flow-
induced dilation (Figure 4A), indicating that, as for the aorta,
active CDMPs are less effective in eliciting endothelial dysfunction
compared to inactive CDMPs (Figure 4A). This reduced efficiency
of active CDMPs to decrease flow-induced dilation resulted in the
decrease of NO-component (Figure 4C) compensated by the
increase of EDHF-component (Figure 4B) without affecting
prostacyclin-component (Figure 4D) of the response.
CDMPs Induce Ex Vivo Vascular Hypo-reactivity in Mouse
Aorta
5-HT produced a concentration-dependent increase in tension
in aortic rings from all groups of mice; however, vascular reactivity
to the agonist was markedly decreased in mice treated with
CDMPs compared to those treated either with vehicle or HSMPs
(Figure 5A). Both inactive and active CDMPs reduced vascular
reactivity to 5-HT to the same extent when compared to vehicle or
HSMPs (Figure 5B). Since no difference of hyporeactivity was
observed between inactive and active CD patients, the mecha-
nisms involved for this process was only investigated in vessels
from mice treated with active CDMPs.
Involvement of NO and O2
2 in Active CDMP-induced
Vascular Hypo-reactivity
To investigate the role of NO, the effect of the NO-synthase
inhibitor, L-NA, was studied on the response to 5-HT. Interest-
ingly, we found that inhibition of the NO pathway did not affect
response to 5-HT in vessels from HSMPs (Figure 6A) but
completely prevented the vascular hypo-reactivity induced by
active CDMPs (Figure 6B). Direct in situ measurements of NO
production were performed by EPR spectroscopy using Fe(-
DETC)2 as a spin trap. Aortas from vehicle, HSMP- and CDMP-
treated mice, exhibited an EPR feature of signals derived from
NO-Fe(DETC)2, being greater in aortas from active CDMP-
treated mice than in vehicle- and HSMP-treated mice (Figure 6C).
Unexpectedly, vascular hypo-reactivity to 5-HT by active
CDMPs was not associated with increased O2
2 production. In
contrast, both HSMPs and active CDMPs reduced O2
2 produc-
tion compared to control (Figure 6D).
CDMPs Increase the Expression of iNOS in Aorta
In order to establish the source of NO, Western blots of aorta of
mice treated with vehicle, HSMPs or CDMPs, were performed. As
shown in Figure 7, MPs from CD patients, but not from HS
patients, markedly enhanced iNOS expression that may explain
the source of increased NO production.
Involvement of COX Metabolites in Active CDMP-induced
Vascular Hypo-reactivity
To investigate the role of COX metabolites in 5-HT-induced
vasoreactivity, the effects of a non-selective inhibitor of COX
Figure 2. Correlations between microparticle (MP) levels and disease activity. Correlations between total circulating MPs, CD41+ MPs,
CD146+ MPs and Harvey-Bradshaw index (A–C).
doi:10.1371/journal.pone.0073088.g002
Table 3. Correlations between circulating MPs level and biological parameters of CD patients.
Circulating MPs AV+ MPs CD41+ MPs CD146+ MPs CD235+ MPs CD62L+ MPs
C-reactive protein (CRP) (mg/L) r’ = 0.56; p= 0.0014 r’ = 0.44; p= 0.011 r’ = 0.51; p= 0.0032 r’ = 0.67; p= 0.0001 r’ = 0.36; p= 0.039 r’ = 0.33; p= 0.056
Albumin (g/L) r’ =2 0.17; p= 0.35 r’ =2 0.14; p= 0.45 r’ =2 0.115; p= 0.53 r’ =2 0.037; p= 0.05 r’ =2 0.21; p= 0.82 r’ =2 0.94; p= 0.61
Platelets (number/mm3) r’ = 0.34; p= 0.058 r’ =2 0.55; p= 0.76 r’ = 0.34; p= 0.06 r’ = 0.165; p= 0.36 r’ = 0.056; p= 0.75 r’ = 0.27; p= 0.14
doi:10.1371/journal.pone.0073088.t003
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(indomethacin) and a selective inhibitor of either COX-1 (SC-560)
or COX-2 (NS398) were examined.
In the presence either of indomethacin or SC-560, contractile
response to 5-HT was reduced in aorta from all groups of mice
(Figure 8A–8D). Meanwhile, vascular hypo-reactivity to 5-HT was
still present in aortas from mice treated with CDMPs compared to
HSMPs or vehicle. These results highlight that vasoconstrictor
metabolite(s) sensitive to indomethacin and SC-560 participate in
5-HT-induced contraction, independently of the MP treatment.
When COX-2 was specifically silenced using NS398, the response
to 5-HT was impaired in vessels from vehicle and HSMP-injected
mice (Figure 8E), suggesting the contribution of COX-2-derived
vasoconstrictor metabolites. In contrast, blockade of COX-2 did
not modify the response induced by active CDMPs (Figure 8F).
Discussion
The present study reports an increased level of circulating MPs
during the active but not inactive state of CD compared to HS,
and detailed the effects of CDMPs on endothelial and vascular
function. Analysis of cellular origin of MPs showed that only MPs
from leukocytes were increased in inactive CD patients whereas
active CD patients displayed increased circulating levels of MPs
from platelets, pro-coagulant, endothelial cells, erythrocytes,
leukocytes, activated leukocytes and activated platelets. Interest-
ingly, a significant correlation was found between total levels of
MPs, those from platelets and endothelial cells, and Harvey-
Bradshaw index.
One of the most important messages of the present study is to
provide evidence of pathophysiological relevance of MPs in CD as
Figure 3. Microparticles (MPs) from CD patients impair endothelium-dependent relaxation in mouse aorta. Acetylcholine (Ach)-
induced relaxation in aortic rings isolated from mice injected in vivo with vehicle (controls (CTL)), MPs from HS (HSMPs) and MPs from CD patients
(CDMPs) (A) subsequently separated in inactive CD patients (inactive CDMPs) (B) and active CD patients (active CDMPs) (B). Results are expressed as a
percentage of U46619-induced pre-contraction and given as mean 6 SEM (n= 5–11). ***p,0.001 vs CTL; {{{p,0.001 vs HSMPs; $$$ p,0.001 active
CDMPs vs inactive CDMPs.
doi:10.1371/journal.pone.0073088.g003
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they strongly alter endothelial and vascular functions. As
previously described for other pathologies [23–25], MPs were
injected at the circulating level of MPs detected in the blood of CD
patients. We observed that several HS patients had circulating
levels of MPs greater than several CD patients, and even in this
case, only MPs from CD patients induced changes in vasomo-
tricity. Thus, the effects observed cannot be related to the different
concentrations of circulating MPs in both groups of subjects, but
rather to the composition of MPs. Despite the important
discoveries related to CD pathophysiology reported during the
last two decades in the fields of genetics, immunology or role of
intestinal microbiota, vascular alterations may participate in CD
lesions. Early observations came from histopathological reports
showing clearly that anatomical lesions and distal vascular
dysfunction were associated to CD (onset and/or more probably
chronic course) [6–10]. Nevertheless, until now, the question
remained to identify at least one factor explaining these
abnormalities.
The present study provides evidence that CDMPs impaired
endothelium-dependent relaxation in response to acetylcholine in
aorta and the endothelial response to flow in SMA (MPs from
inactive CD patients being more deleterious than those from active
CD patients, a fact still remaining to be explained). These data
contribute to explain – at least in part – several mechanisms
participating in CD pathophysiology, especially in the long-term
course of the disease. As shown, due to their impact on vascular
function, MPs probably contribute to mesenteric thrombosis and
multifocal mesenteric ischemic infarction in distal SMA. They may
also induce endothelial dysfunction that is the primary event
leading to the failure of vasoactive, anti-coagulant and anti-
inflammatory effects of healthy endothelium. These data strongly
suggest that CDMPs are able to induce ex vivo endothelial
dysfunction and demonstrate one of their pathophysiological
relevance in CD. These data are in accordance with our former
works with MPs isolated from patients with preeclampsia,
metabolic syndrome and obstructive sleep apnoea [23,25,27,34].
Unexpectedly, MPs from inactive CD patients were more
deleterious than those from active CD patients. Thus, firstly
endothelial dysfunction still occurs during the inactive state.
Secondly, one can advance the hypothesis of a potential attempt
by the organism in the active phase of disease to partially offset
these deleterious effects of MPs towards the endothelium. Indeed
in SMA, the reduced NO-component of flow-induced vasodilata-
tion was compensated by an increased EDHF-component of the
response in vessels taken from mice treated with MPs from active
CD patients. Thirdly, it is possible that the deleterious effects of
leukocyte-derived MPs are counterbalanced, at least partially, by
the other types of MPs (from platelets, erythrocytes, endothelial
cells and those expressing L-selectin and P-selectin) (see below).
These results may provide new information about the impact of
disease activity on endothelial dysfunction observed in CD
patients. Indeed, the results obtained in literature are conflicting.
On the one hand, it has been reported elevated levels of
asymmetric dimethylarginine, an endothelial dysfunction marker,
in the serum of CD patients and these increased levels are
positively correlated with the disease activity [35]. On the other
hand, Roifman and coworkers did not observe the relationship
between disease duration or clinical disease activity and micro-
vascular endothelial dysfunction directly assessed in CD patients
[36].
Figure 4. Microparticles (MPs) from CD patients impair flow-induced dilation in small mesenteric arteries. Flow-induced dilatation
obtained in small mesenteric arteries isolated from mice injected in vivo with vehicle (controls (CTL)), MPs from HS (HSMPs) and MPs from inactive CD
patients (inactive CDMPs) and active CD patients (active CDMPs) (A). Dilation expressed in mm in response to flow expressed in mL/min: dilation
dependent to endothelium-derived hyperpolarizing factor (EDHF) (B), to nitric oxide (NO) (D), and to cyclooxygenase products prostaglandin (PGI2)
(D). Results are given as mean 6 SEM (n= 5–10). ***p,0.001 vs CTL; {{{p,0.001 vs HSMPs; $$$ p,0.001 active CDMPs vs inactive CDMPs.
doi:10.1371/journal.pone.0073088.g004
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Interestingly, CDMPs promoted vascular hypo-reactivity by
inducing the production of NO, decreasing O2
2 content and
altering the release of COX metabolites especially those from
COX-2. The consequence of these alterations probably results in
distal mesenteric vascular collapse, subsequent SMA occlusion,
and finally the resulting local inflammation and tissue injury as
observed in CD patients with active disease (or inactive disease;
despite there were no macroscopic lesions in these patients,
mucosal biochemical inflammation has been shown to be still
present [16]). Indeed, MPs from both inactive and active CD
patients are able to promote vascular hyporeactivity in response to
5-HT in mouse aorta. The fact that i.v. injection of MPs did not
decrease systolic blood pressure (not shown) suggests that other
factors are able to counteract the in vivo effects of MPs on systemic
blood pressure or MPs might be involved in local inflammation
and tissue injury only. These findings are in line with our previous
studies on other disease such as preeclampsia, diabetes and
metabolic syndrome [33,34,37]. In these pathologies, MPs induce
vascular hyporeactivity by a mechanism that involves NO and
COX pathways through enhanced expression of iNOS and COX-
2 with subsequent increased NO and prostacyclin production,
respectively. Altogether, these results suggest that CDMPs are able
to act on smooth muscle and induce the release of vasodilator
factors, at least NO without modification of oxidative stress, or
alternatively, CDMPs evoke alteration of the balance between
vasoconstrictor and/or relaxant factors (COX-2 metabolites) in
smooth muscle cells. In the present study, we show that CDMPs
induce an increase of iNOS expression accounting for the increase
of NO production that explains the capacity of CDMPs to prevent
the vasoconstriction. The excessive NO production observed in
vascular tissue after administration of CDMPs, might suggest a
deleterious effect by inducing nitration in tissues. Indeed, NO may
interact with superoxide anion and produce peroxynitrite which
can nitrate proteins. However, no effect on nitration was observed
between the three groups of mice (not shown) indicating that NO
affect endothelial relaxation and vascular reactivity by other
mechanisms than protein nitration. In line with our results, we
have reported in SMA isolated from inflamed CD colon a marked
iNOS and COX-2 expressions and a balance between vasocon-
strictor products from COX-2 and unknown vasodilator products
that maintained vascular reactivity in a physiological range [15].
In the present study, we highlight the fact that MPs from CD
patients play a significant role in vascular dysfunction including
reduced response to vasoconstrictor agents. Thus, CDMPs could
be considered as important mediators of inflammatory process that
characterizes CD.
Platelet and endothelial MPs probably participate in the severity
of the disease. With respect to increased platelet MPs, our data are
in accordance with those reported in the literature using a new tool
in the evaluation of thrombotic and bleeding disorders, the
endogenous thrombin potential (ETP), the increase of which is
related to the activity of this disease [38]. Very recently, it has been
also reported an increased pro-coagulant function of MPs in
pediatric patients in both active and quiescent CD compared with
HS patients [39]. Regarding the involvement of endothelial MPs,
an increased level of this type of MPs has been observed in several
pro-inflammatory and prothrombotic pathological states such as
pulmonary hypertension, venous thromboembolism and acute
coronary syndrome [40–42]. Furthermore, endothelial MPs play a
role in mechanism of coagulation, inflammation and angiogenesis
[43]. Thus, the combination of these populations of MPs may
participate in the inflammatory process inasmuch they can induce
neutrophil and endothelial activation, monocyte adhesion, and
recruitment of different inflammatory cells [18,20]. However, the
fact that the sole difference between HS and inactive CD patients
regarding the type of MPs is the increase of the leukocyte-derived
MPs in inactive CD patients suggest, on the one hand, that, during
CD, both activation of leukocytes and MP release from these cells
are enhanced, and on the other hand that leukocyte-derived MPs
support, at least partially, the deleterious effect of MPs.
Limitations of the study: Only three studies investigated the
possible role of MPs as biomarkers of the CD. The first article
reports that increased circulating MPs could be linked to the type
of inflammatory response underlying CD although the amounts of
MPs do not correlate with disease activity [29]. It is important to
note that only pro-coagulant MPs (annexin V+) were explored with
the technique used. The cellular origin of these pro-coagulant MPs
was mainly from platelets with low amounts from leukocytes. The
second study measured only MPs from platelets and demonstrates
that they are elevated in active but not inactive CD and correlate
with disease activity and soluble P-selectin, suggesting that platelet
MPs may be useful markers to evaluate activated state of platelets
in this disease [30]. A third study published recently, reported a
significant increase in tissue factor exposing MPs in IBD patients,
Figure 5. Microparticles (MPs) from CD patients decrease 5-HT
contraction in mouse aorta. Concentration-effect curves in response
to 5-HT in aortic rings isolated from mice injected in vivo with vehicle
(controls (CTL)), MPs from HS (HSMPs) and MPs from CD patients
(CDMPs) (A) subsequently separated in inactive CD patients (inactive
CDMPs) (B) and active CD patients (active CDMPs) (B). Contraction are
expressed in mN/mm. Results are given as mean 6 SEM (n=6–13).
**p,0.01, ***p,0.001 vs CTL; {{p,0.001, {{{p,0.001 vs HSMPs.
doi:10.1371/journal.pone.0073088.g005
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but even their main objective was to explore their association to
haemostasis activation, they also studied association to disease
activity and CRP concentrations but found no significant
correlations [44]. The present study highlighted a significant
correlation between total levels of MPs, those from platelets and
endothelial cells, and Harvey-Bradshaw index in a small cohort of
patients. Altogether, although interesting, the use of MPs as
biomarkers of CD needs to be explored on a much larger patients’
cohort, on longitudinal basis and a more detailed characterization
of discriminated proteins and/or miRNAs carried by MPs.
In conclusion, the present study demonstrates that CDMPs
should be considered as important factors in CD pathophysiology.
It is not known if the induced endothelial and vascular dysfunction
plays a role at the early stages of the disease and/or later. But the
alterations induced by CDMPs, undoubtedly play a role in long-
term intestinal damage and probably explain – at least in part –
the vascular anatomical and functional abnormalities described
several decades ago. Moreover, MPs not only should be
considered as triggers of endothelial dysfunction, but also as
effectors (i) able to amplify pre-existing vascular dysfunction,
including vascular hypo-reactivity, (ii) possibly able to increase the
prothrombotic status reported in CD, (iii) able to participate to the
maintenance of chronic (even sub-clinical) inflammation, or (iv)
contributing to extra-intestinal CD manifestations due to their
ability to reach easily other organs than the gut.
Figure 6. Microparticles (MPs) from active CD patients induce nitric oxide (NO) overproduction in mouse aorta. Concentration-effect
curves of 5-HT in the presence and in the absence of L-NA in aortic rings isolated from mice injected in vivo with vehicle (controls (CTL)) and MPs
from HS (HSMPs) (A) and with MPs from active CD patients (active CDMPs) (B). Contraction are expressed in mN/mm. Results are given as mean 6
SEM (n=7–8). NO production (C) assessed by the amplitude of NO-Fe(DETC)2 complex signal and superoxide anion (O2
2) production (D) assessed by
the amplitude of O2
–CMH complex signal in unit/weight in aorta from mice injected in vivo with vehicle (CTL), HSMPs and active CDMPs. Results are
given as mean 6 SEM (n= 5–7). **p,0.01; ***p,0.001 vs CTL.
doi:10.1371/journal.pone.0073088.g006
Figure 7. MPs from active CD patients increase the expression
of iNOS in aorta. The aortas were isolated from mice injected with
vehicle (CTL), MPs from healthy subjects (HSMPs) or with MPs from
active CD patients (CDMPs). Western blotting was probed using
antibodies raised against iNOS. Immunoblots were quantified by
densitometric analysis. Data are representative of five separate blots,
and the densitometry values are expressed in arbitrary units (A.U.) as
mean 6 SEM. *P,0.05 versus CTL.
doi:10.1371/journal.pone.0073088.g007
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